Search

Your search keyword '"Gallardo, David"' showing total 196 results
Start Over Author "Gallardo, David" Publication Type Academic Journals
196 results on '"Gallardo, David"'

5. Front-line fludarabine-cyclophosphamide-rituximab (FCR) in 110 patients with chronic lymphocytic leukaemia (CLL): real-life experience with long-term outcomes, toxicities and responses to second-line therapies

Author

Oliveira, Ana C., Roncero, Josep Maria, Ferrá, Christelle, Do Nascimento, Janilson, Rodriguez-Luaces, Marta, Encuentra, Maite, Domingo-Domenech, Eva, López, Patricia, Gallardo, David, Ribera, Josep Maria, Sarrá, Josep, Sureda, Anna, and González-Barca, Eva

Published
2023
Full Text
View/download PDF

6. Risk prediction of CMV reactivation after allogeneic stem cell transplantation using five non-HLA immunogenetic polymorphisms

Author

Vallejo, Miren, Muñiz, Paula, Kwon, Mi, Solán, Laura, Bailén, Rebeca, Carbonell, Diego, Chicano, María, Suárez-González, Julia, Catalán, Pilar, Bellón, José María, Triviño, Juan Carlos, Dorado, Nieves, Gallardo, David, Díez-Martín, José Luis, Ramírez, Natalia, Martínez-Laperche, Carolina, and Buño, Ismael

Published
2022
Full Text
View/download PDF

7. European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol

Author

Bataller, Alex, Garrido, Ana, Guijarro, Francesca, Oñate, Guadalupe, Diaz-Beyá, Marina, Arnan, Montserrat, Tormo, Mar, Vives, Susana, de Llano, María Paz Queipo, Coll, Rosa, Gallardo, David, Vall-Llovera, Ferran, Escoda, Lourdes, Garcia-Guiñon, Antonio, Salamero, Olga, Sampol, Antònia, Merchan, Brayan M., Bargay, Joan, Castaño-Díez, Sandra, Esteban, Daniel, Oliver-Caldés, Aina, Rivero, Andrea, Mozas, Pablo, López-Guerra, Mònica, Pratcorona, Marta, Zamora, Lurdes, Costa, Dolors, Rozman, Maria, Nomdedéu, Josep F., Colomer, Dolors, Brunet, Salut, Sierra, Jorge, and Esteve, Jordi

Published
2022
Full Text
View/download PDF

8. Grado de dependencia basal en actividades básicas e instrumentales de la vida diaria como factor predictivo de supervivencia de los pacientes dados de alta de la Unidad de Cuidados Intensivos de un hospital público de la ciudad de Santiago de Chile, en un período de 5 años.

Author

Miguel Arancibia, José, Ebner, Matías, Gallardo, David, Aravena, Florencia, Muñoz, Álex, Hurtado, Javier, Gómez, Carlos, Caniguante, Guillermina, Bozzano, Gala, Barrios, Paulina, Bustamante, Carmen, Gallegos, Sebastián, and Eduardo Sánchez, Juan

Subjects
PUBLIC hospitals, HOSPITAL care, CATASTROPHIC illness, DISCHARGE planning, DESCRIPTIVE statistics, LONGITUDINAL method, INTENSIVE care units, SURVIVAL analysis (Biometry), DEPENDENCY (Psychology)
Abstract

Copyright of Revista Argentina de Terapia Intensiva is the property of Sociedad Argentina de Terapia Intensiva (SATI) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2024

9. Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Transplantation Seems Less Efficacious in Poor Mobilizers with the Use of a Biosimilar of Filgrastim and Plerixafor: A Retrospective Comparative Analysis

Author

Parody, Rocío, Sánchez-Ortega, Isabel, Ferrá, Christelle, Guardia, Ramon, Talarn, Carme, Encuentra, Maite, Fort, Eduard, López, David, Morgades, Mireia, Alonso, Eva, Ortega, Sandra, Sarrá, Josep, Gallardo, David, Ribera, Josep M., and Sureda, Anna

Published
2020
Full Text
View/download PDF

12. A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms

Author

Martínez-Laperche, Carolina, Buces, Elena, Aguilera-Morillo, M. Carmen, Picornell, Antoni, González-Rivera, Milagros, Lillo, Rosa, Santos, Nazly, Martín-Antonio, Beatriz, Guillem, Vicent, Nieto, José B., González, Marcos, de la Cámara, Rafael, Brunet, Salut, Jiménez-Velasco, Antonio, Espigado, Ildefonso, Vallejo, Carlos, Sampol, Antonia, Bellón, José María, Serrano, David, Kwon, Mi, Gayoso, Jorge, Balsalobre, Pascual, Urbano-Izpizua, Álvaro, Solano, Carlos, Gallardo, David, Díez-Martín, José Luis, Romo, Juan, and Buño, Ismael

Published
2018
Full Text
View/download PDF

15. Donor CTLA-4 Genotype Modulates the Immune Response to Minor Histocompatibility Antigen Mismatches

Author

Gallardo, David, Bosch-Vizcaya, Anna, Rodríguez-Romanos, Rocío, Santos, Nazly, Buño, Ismael, de la Cámara, Rafael, Brunet, Salut, Jiménez-Velasco, Antonio, González, Marcos, Nieto, Jose B., Martínez-Laperche, Carolina, Vallejo, Carlos, Ferrá, Christelle, Sampol, Antònia, López-Jiménez, Javier, Pérez-Simón, Jose A., Martínez, Carmen, and Díez, Jose L.

Published
2017
Full Text
View/download PDF

16. CD200 genotype is associated with clinical outcome of patients with multiple myeloma.

Author

Gonzalez-Montes, Yolanda, Osca-Gelis, Gemma, Rodriguez-Romanos, Rocío, Villavicencio, Alicia, González-Bártulos, Marta, Llopis, Francesca, Clapes, Victòria, Oriol, Albert, Sureda, Anna, Escoda, Lourdes, Sarrà, Josep, Garzó, Ana, Lloveras, Natàlia, Gómez, Beatriz, Granada, Isabel, and Gallardo, David

Subjects
MULTIPLE myeloma, IMMUNE checkpoint proteins, GENOTYPES, STEM cell transplantation, MULTIVARIATE analysis
Abstract

Immune dysfunction in patients with MM affects both the innate and adaptive immune system. Molecules involved in the immune response pathways are essential to determine the ability of cancer cells to escape from the immune system surveillance. However, few data are available concerning the role of immune checkpoint molecules in predicting the myeloma control and immunological scape as mechanism of disease progression. We retrospectively analyzed the clinical impact of the CD200 genotype (rs1131199 and rs2272022) in 291 patients with newly diagnosed MM. Patients with a CD200 rs1131199 GG genotype showed a median overall survival (OS) significantly lower than those with CC+CG genotype (67.8 months versus 94.4 months respectively; p: 0.022) maintaining significance in the multivariate analysis. This effect was specially detected in patients not receiving an autologous stem cell transplant (auto-SCT) (p < 0.001). In these patients the rs1131199 GG genotype negatively influenced in the mortality not related with the progression of MM (p: 0.02) mainly due to infections events. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. PD-1 genotype of the donor is associated with acute graft-versus-host disease after HLA-identical sibling donor stem cell transplantation

Author

Santos, Nazly, Rodríguez-Romanos, Rocío, de la Cámara, Rafael, Brunet, Salut, Nieto, Jose B., Buño, Ismael, Martínez, Carmen, Jiménez-Velasco, Antonio, Vallejo, Carlos, González, Marcos, Solano, Carlos, Ferrá, Christelle, Sampol, Antonia, Pérez-Simón, Jose A., López-Jiménez, Javier, Díez, José L., Gallardo, David, and On behalf of the GvHD/Immunotherapy Working Party of the Spanish Group of Hematopoietic Transplant (GETH)

Published
2018
Full Text
View/download PDF

18. Serum Galactomannan Versus a Combination of Galactomannan and Polymerase Chain Reaction–Based Aspergillus DNA Detection for Early Therapy of Invasive Aspergillosis in High-Risk Hematological Patients: A Randomized Controlled Trial

Author

PCRAGA Study Group, the Spanish Stem Cell Transplantation Group, the Study Group of Medical Mycology of the Spanish Society of Clinical Microbiology and Infectious Diseases, and the Spanish Network for Research in Infectious Diseases, Aguado, José María, Vázquez, Lourdes, Fernández-Ruiz, Mario, Villaescusa, Teresa, Ruiz-Camps, Isabel, Barba, Pere, Silva, Jose T., Batlle, Montserrat, Solano, Carlos, Gallardo, David, Heras, Inmaculada, Polo, Marta, Varela, Rosario, Vallejo, Carlos, Olave, Teresa, López-Jiménez, Javier, Rovira, Montserrat, Parody, Rocío, and Cuenca-Estrella, Manuel

Published
2015

21. Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma.

Author

Gonzalez-Montes, Yolanda, Rodriguez-Romanos, Rocío, Villavicencio, Alicia, Osca-Gelis, Gemma, González-Bártulos, Marta, Llopis, Francesca, Clapes, Victòria, Oriol, Albert, Sureda, Anna, Escoda, Lourdes, Sarrà, Josep, Garzó, Ana, Lloveras, Natàlia, Díez, Isabel, Granada, Isabel, and Gallardo, David

Subjects
GENETIC variation, MULTIPLE myeloma, IMMUNE checkpoint proteins, PROGRESSION-free survival, MULTIVARIATE analysis, PROGRAMMED cell death 1 receptors
Abstract

Immune dysfunction in patients with multiple myeloma (MM) affects both the innate and adaptive immune system. Molecules involved in the immune checkpoint pathways are essential to determine the ability of cancer cells to escape from the immune system surveillance. However, few data are available concerning the role of these molecules in predicting the kinetics of progression of MM. We retrospectively analysed polymorphisms of CTLA4 (rs231775 and rs733618), BTLA (rs9288953), CD28 (rs3116496), PD-1 (rs36084323 and rs11568821) and LAG-3 (rs870849) genes in 239 patients with newly diagnosed MM. Patients with a CTLA4 rs231775 AA/AG genotype showed a median progression-free survival (PFS) significantly lower than those with GG genotype (32.3 months versus 96.8 months respectively; p: 0.008). The 5-year PFS rate was 25% for patients with grouped AA and AG genotype vs 55.4% for patients with GG genotype. Multivariate analysis confirmed the CTLA4 rs231775 genotype as an independent risk factor for PFS (Hazard Ratio (HR): 2.05; 95% CI: 1.0-6.2; p: 0.047). Our results suggest that the CTLA4 genotype may identify patients with earlier progression of MM. This polymorphism could potentially be used as a prognostic biomarker. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

24. Donor CTLA-4 Genotype Influences Clinical Outcome after T Cell-Depleted Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Identical Sibling Donors

Author

Bosch-Vizcaya, Anna, Pérez-García, Arianne, Brunet, Salut, Solano, Carlos, Buño, Ismael, Guillem, Vicent, Martínez-Laperche, Carolina, Sanz, Guillermo, Barrenetxea, Cristina, Martínez, Carmen, Tuset, Esperanza, Lloveras, Natàlia, Coll, Rosa, Guardia, Ramon, González, Yolanda, Roncero, Josep M., Bustins, Anna, Gardella, Santiago, Fernández, Cristalina, Buch, Joan, and Gallardo, David

Published
2012
Full Text
View/download PDF

26. Genetic characterization of acute myeloid leukemia patients with mutations in IDH1/2 genes

Author

Acha, Pamela, Hoyos, Montserrat, Pratcorona, Marta, Fuster-Tormo, Francisco, Palomo, Laura, Ortega, Esther, Zamora, Lurdes, Vives, Susana, Granada, Isabel, Montoro, Julia, Garcia, Antoni, Arnan, Montserrat, Cervera, Marta, Canet, Marta, Gallardo, David, Arenillas, Leonor, Esteve, Jordi, Baragay, Joan, Salamero, Olga, Motlló, Cristina, Ortín, Xavier, Sierra, Jordi, and Solé, Francesc

Published
2021
Full Text
View/download PDF

27. Ubtf tandem Duplications Define a Novel Subtype of Acute Myeloid Leukemia Associated with Younger Age, WT1 Mutations and HOXA9 Marked Overexpression

Author

Castellet, Helena, Ramil López, Guillermo, Garrido, Ana, Artigas-Baleri, Alícia, Pratcorona, Marta, Salamero, Olga, Cortés-Bullich, Albert, Vives, Susana, Tormo, Mar, Mascaro Riera, Martin, Gallardo, David, Marti Tutusaus, Josep Maria, Garcia, Antonio, Sierra, Jorge, Esteve, Jordi, and Nomdedeu, Josep

Published
2023
Full Text
View/download PDF

28. Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantation.

Author

Muñiz, Paula, Andrés-Zayas, Cristina, Carbonell, Diego, Chicano, María, Bailén, Rebeca, Oarbeascoa, Gillen, Suárez-González, Julia, Gómez Centurión, Ignacio, Dorado, Nieves, Gallardo, David, Anguita, Javier, Kwon, Mi, Díez-Martín, Jose L., Martínez-Laperche, Carolina, and Buño, Ismael

Subjects
HEMATOPOIETIC stem cell transplantation, STEM cell transplantation, CURATIVE medicine, GENETIC polymorphisms, SINGLE nucleotide polymorphisms, CYCLOPHOSPHAMIDE, HEPATIC veno-occlusive disease, ALKYLATING agents
Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment for patients with hematologic malignances. Haploidentical HSCT (Haplo-HSCT) is an alternative option for patients who do not have an HLAmatched donor. The use of post-transplantation high dose cyclophosphamide (PT-Cy) is commonly employed for graft-versus-host disease (GVHD) prophylaxis in haplo-HSCT. Cyclophosphamide (Cy) is an alkylating agent with antineoplastic and immunosuppressive activity, whose bioactivation requires the activity of polymorphic enzymes in the liver to produce phosphoramide mustard, which is a DNA alkylating agent. To identify polymorphisms in the genes of Cy metabolism and correlate them with post-HSCT complications [GVHD, sinusoidal obstruction syndrome (SOS), hemorrhagic cystitis (HC) and transplant-related mortality (TRM)], we designed a custom next-generation sequencing panel with Cy metabolism enzymes. We analyzed 182 patients treated with haplo-HSCT with PT-Cy from 2007 to 2019, detecting 40 variants in 11 Cy metabolism genes. Polymorphisms in CYP2B6, a major enzyme involved in Cy activation, were associated with decreased activity of this enzyme and a higher risk of Graf-versus-host disease (GVHD). Variants in other activation enzymes (CYP2A6, CYP2C8, CYP2C9, CYP2C19) lead to decreased enzyme activity and were associated with GVHD. Polymorphisms in detoxification genes such as glutathione S-transferases decreased the ability to detoxify cyclophosphamide metabolites due to lower enzyme activity, which leads to increased amounts of toxic metabolites and the development of III-IV acute GVHD. GSMT1*0 a single nucleotide polymorphism previously recognized as a risk factor for SOS was associated with a higher risk of SOS. We conclude that polymorphisms of genes involved in the metabolism of cyclophosphamide in our series are associated with severe grades of GVHD and toxicities (SOS and TRM) after haplo-HSCT and could be used to improve the clinical management of transplanted patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

29. CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors.

Author

Pérez-García, Arianne, De la Cámara, Rafael, Román-Gómez, Jose, Jiménez-Velasco, Antonio, Encuentra, Maite, Nieto, Jose B., de la Rubia, Javier, Urbano-Ispizúa, Alvaro, Brunet, Salut, Iriondo, Arturo, González, Marcos, Serrano, David, Espigado, Ildefonso, Solano, Carlos, Ribera, Josep M., Pujal, Josep M., Hoyos, Montserrat, and Gallardo, David

Published
2007
Full Text
View/download PDF

32. Hybrid Glide-Symmetric Unit Cell for Leakage Reduction in Millimeter-Wave PCB Interconnections to Waveguide Components.

Author

Gonzalez-Gallardo, David, Algaba-Brazalez, Astrid, Manholm, Lars, Johansson, Martin, and Quevedo-Teruel, Oscar

Subjects
*UNIT cell, *LEAKAGE, *PRINTED circuits, *AIR gap (Engineering)
Abstract

In this article, we propose a hybrid glide-symmetric metasurface which presents an electromagnetic bandgap (EBG) behavior at the $Ka$ -band. The innovative part of this work is the hybrid nature of the periodic structure, which is implemented with holes on two different technologies: printed circuit board (PCB) and metallic waveguide. These holes avoid propagation in an undesired parallel plate created between a PCB and a metallic waveguide. To demonstrate the potential of this concept, a hybrid glide-symmetric configuration was placed surrounding a PCB–waveguide transition at the $Ka$ -band to reduce the leakage created by undesired air gaps. A prototype was manufactured and measured to corroborate the effectiveness of this technique to reduce losses and crosstalk. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

34. Disparity for the minor histocompatibility antigen HA-1 is associated with an increased risk of acute graft-versus-host disease (GvHD) but it does not affect chronic GvHD incidence, disease-free survival or overall survival after allogeneic human leucocyte antigen-identical sibling donor transplantation

Author

Gallardo, David, Aróstegui, Juan Ignacio, Balas, Antonio, Torres, Antonio, Caballero, Dolores, Carreras, Enric, Brunet, Salut, Jiménez, Antonio, Mataix, Rodolfo, Serrano, David, Vallejo, Carlos, Sanz, Guillermo, Solano, Carlos, Rodríguez-Luaces, Marta, Marín, Julián, Baro, Julio, Sanz, César, Román, Jose, González, Marcos, Martorell, Jaume, Sierra, Jorge, Martín, Carmen, de la Cámara, Rafael, and Grañena, Albert

Published
2001

36. Meta-Analysis of Genome-Wide Association and Gene Expression Studies Implicates Donor T Cell Function and Cytokine Pathways in Acute GvHD.

Author

Hyvärinen, Kati, Koskela, Satu, Niittyvuopio, Riitta, Nihtinen, Anne, Volin, Liisa, Salmenniemi, Urpu, Putkonen, Mervi, Buño, Ismael, Gallardo, David, Itälä-Remes, Maija, Partanen, Jukka, and Ritari, Jarmo

Subjects
GENE expression, CELL physiology, T cells, HEMATOPOIETIC stem cell transplantation, HLA histocompatibility antigens, GENE ontology
Abstract

Graft-vs.-host disease (GvHD) is a major complication after allogeneic hematopoietic stem cell transplantation that causes mortality and severe morbidity. Genetic disparities in human leukocyte antigens between the recipient and donor are known contributors to the risk of the disease. However, the overall impact of genetic component is complex, and consistent findings across different populations and studies remain sparse. To gain a comprehensive understanding of the genes responsible for GvHD, we combined genome-wide association studies (GWAS) from two distinct populations with previously published gene expression studies on GvHD in a single gene-level meta-analysis. We hypothesized that genes driving GvHD should be associated in both data modalities and therefore could be detected more readily through their combined effects in the integrated analysis rather than in separate analyses. The meta-analysis yielded a total of 51 acute GvHD-associated genes (false detection rate [FDR] <0.1). In support of our hypothesis, this number was significantly higher than that in a permutation meta-analysis involving the whole data set, as well as in separate meta-analyses on the GWAS and gene expression data sets. The genes indicated by the meta-analysis were significantly enriched in 277 Gene Ontology terms (FDR < 0.05), such as T cell function and cytokine-mediated signaling pathways, and the results highlighted several established immune mediators, such as interleukins and JAK-STAT signaling, and presented TRAF6 and TERT as potential effector candidates. Altogether, the results support the chosen methodological approach, implicate a role of gene-level variation in donors' key immunological regulators predisposing patients to acute GVHD, and present potential targets for therapeutic intervention. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

37. Prospective Population-Based Analysis of Characteristics and Therapy Options in AML: The Case of Catalonia (PERIS Project)

Author

Hoyos, Montserrat, Garrido, Ana, Arnan, Montserrat, Diaz-Beyá, Marina, Salamero, Olga, Vives, Susana, Garcia-Guiñon, Antonio, Gallardo, David, Cervera, Marta, Vall-Llovera, Ferran, Motlló, Cristina, Merchan, Brayan, Roig Martinez, Imma, Ortin, Xavier, Olivera, Pável E, Sureda Balari, Anna, Valcarcel, David, Ribera, Josep-Maria, Esteve, Jordi, and Sierra, Jorge

Published
2020
Full Text
View/download PDF

38. Risk-Adapted Intensive Chemotherapy for Primary ACUTE Myeloid Leukemia during the Last 25 YEARS: Increase in Complete Remission RATE, Hematopoietic Cell Transplantation Access and Decrease in Relapse Incidence Have LED to Improved Survival

Author

Garrido, Ana, Hoyos, Montserrat, Diaz-Beyá, Marina, Arnan, Montserrat, Vives, Susana, Calabuig, Marisa, Salamero, Olga, Gallardo, David, Queipo De Llano, Maria Paz, Escoda, Lourdes, Sampol, Antonia, Vall-Llovera, Ferran, Garcia-Guiñon, Antonio, Brayan, Merchan, Bargay, Joan, Torres, J Pio, Ortin, Xavier, Amigo, M Luz, Moraleda, Jose Maria, Falantes, José F., Valcarcel, David, Tormo, Mar, Ribera, Josep-Maria, Brunet, Salut, Sureda Balari, Anna, Esteve, Jordi, and Sierra, Jorge

Published
2020
Full Text
View/download PDF

39. Acute Myeloid Leukemia with Isocitrate Dehydrogenases (IDH) 1 and 2 Mutations. a Real-World Study from the European IDH Research Group

Author

Maggioni, Giulia, Tentori, Cristina Astrid, Voso, Maria Teresa, Heibl, Sonja, Metzeler, Klaus H., Middeke, Jan Moritz, Desterro, Joana, Carmo-Fonseca, Maria, Travaglino, Erica, Fazi, Paola, Piciocchi, Alfonso, Dufour, Annika Maria, Esteve, Jordi, Pratcorona, Marta, Mancini, Valentina, Lussana, Federico, Spiekermann, Karsten, Thiede, Christian, Stolzel, Friedrich, Botelho de Sousa, Aida, Tormo, Mar, Acha, Pamela, Arnan, Montserrat, Fracchiolla, Nicola, Hentrich, Marcus, Sippel, Christoph, Heilmeier, Bernhard, Lemos, Marcos, Nunes, Albertina, Matos, Sonia, Diaz, Marina, Garrido, Ana, Gallardo, David, Vives, Susana, Salamero, Olga, Todisco, Elisabetta, Basilico, Claudia, Passamonti, Francesco, Machherndl-Spandl, Sigrid, Pleyer, Lisa, Sierra, Jorge, Solé, Francesc, and Della Porta, Matteo Giovanni

Published
2020
Full Text
View/download PDF

40. Validation of the European Leukemianet 2017 Prognostic Classification for Patients with De Novo Acute Myeloid Leukemia Treated with a Risk-Adapted Protocol (CETLAM 2012)

Author

Bataller, Alex, Garrido, Ana, Guijarro, Francesca, Diaz-Beyá, Marina, Oñate, Guadalupe, Hoyos, Montserrat, Arnan, Montserrat, Tormo, Mar, Vives, Susana, Queipo De Llano, Maria Paz, Salamero, Olga, Coll, Rosa, Gallardo, David, Vall-Llovera, Ferran, Escoda, Lourdes, Sampol, Antonia, Garcia-Guiñon, Antonio, Merchan, Brayan, Bargay, Joan, Lopez-Guerra, Monica, Pratcorona, Marta, Zamora, Lurdes, Brunet, Salut, Nomdedeu, Josep F, Sierra, Jorge, and Esteve, Jordi

Published
2020
Full Text
View/download PDF

41. Final Results of the AML12 Trial of the Spanish Cetlam Group in Adults with Acute Myeloid Leukemia (AML) up to the Age of 70 Years: Risk Adapted Post-Remission Allocation Based on Genetic Data and Minimal Residual Disease

Author

Sierra, Jorge, Garrido, Ana, Diaz Beya, Marina, Hoyos, Montserrat, Calabuig, Marisa, Vives, Susana, Arnan Sangerman, Montserrat, Queipo De Llano, Maria Paz, Salamero, Olga, Vall-Llovera, Ferran, Bataller, Alex, Guijarro, Francisca, Escoda, Lourdes, Garcia-Guiñon, Antonio, Merchan, Brayan, Ortin, Xavier, Sanchez Ortega, Isabel, Pratcorona, Marta, Bargay, Joan, Sampol, Antonia, Nomdedeu, Josep, Gallardo, David, Ribera, Josep-Maria, Tormo, Mar, Esteve, Jordi, and Brunet, Salut

Published
2019
Full Text
View/download PDF

42. Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival.

Author

Guillem, Vicent, Calabuig, Marisa, Brunet, Salut, Esteve, Jordi, Escoda, Lourdes, Gallardo, David, Ribera, Josep-Maria, Queipo de Llano, María Paz, Arnan, Montserrat, Pedro, Carme, Amigo, María Luz, Martí-Tutusaus, Josep M., García-Guiñón, Antoni, Bargay, Joan, Sampol, Antonia, Salamero, Olga, Font, Llorenç, Talarn, Carme, Hoyos, Montserrat, and Díaz-Beyá, Marina

Subjects
VASCULAR endothelial growth factors, LEUKEMIA, NEOVASCULARIZATION, ACUTE myeloid leukemia, CYTOGENETICS
Abstract

Vascular endothelial growth factor C (VEGFC) stimulates leukemia cell proliferation and survival, and promotes angiogenesis. We studied VEGFC expression in bone marrow samples from 353 adult acute myeloid leukemia (AML) patients and its relationship with several clinical, cytogenetic, and molecular variables. We also studied the expression of 84 genes involved in VEGF signaling in 24 patients. We found that VEGFC expression was higher in AML patients with myelodysplasia-related changes (AML-MRC) than in patients with non-AML-MRC. We also found an association between VEGFC expression and the patient cytogenetic risk group, with those with a worse prognosis having higher VEGFC expression levels. No correlation was observed between VEGFC expression and survival or complete remission. VEGFC expression strongly correlated with expression of the VEGF receptors FLT1, KDR, and NRP1. Thus, in this series, VEGFC expression was increased in AML-MRC and in subgroups with a poorer prognosis, but has no impact on survival. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

45. Therapy for Acute Myeloid Leukemia (AML) Adjusted to Genetic Data and Minimal Residual Disease: Results of the AML12 Trial of the Spanish Cetlam Group in Adults up to the Age of 70 Years

Author

Sierra, Jorge, Garrido, Ana, Vives, Susana, Queipo De Llano, Maria Paz, Guàrdia, Ramon, Diaz-Beyá, Marina, Calabuig, Marisa, Pratcorona, Marta, Arnan Sangerman, Montserrat, Salamero, Olga, Cervera, Marta, Sampol, Antonia, Garcia-Guiñon, Antoni, Pedro, Carme, Marti, Josep M, Bargay, Joan, Font, Llorenç, Nomdedeu, Josep F, Hoyos, Montserrat, Escoda, Lourdes, Batlle, Montserrat, Merchan, Bryan, Sanchez-Ortega, Isabel, Tormo, Mar, Gallardo, David, Ribera, Josep-Maria, Esteve, Jordi, and Brunet, Salut

Published
2017
Full Text
View/download PDF

48. Highly variable mutational profile of ASXL1 in myelofibrosis.

Author

Sorigué, Marc, Ribera, Josep‐Maria, García, Olga, Cabezón, Marta, Vélez, Patricia, Marcé, Silvia, Xicoy, Blanca, Fernández, Cristalina, Buch, Joan, Cortes, Montserrat, Plensa, Esther, Gallardo, David, Boqué, Concepción, Feliu, Evarist, and Zamora, Lurdes

Subjects
MYELOFIBROSIS, MYELOPROLIFERATIVE neoplasms, SOMATIC mutation, GENETIC mutation, PROGNOSTIC tests
Abstract

Objective Somatic mutations in ASXL1 seem to have a negative prognostic impact in patients with several myeloid neoplasms, including myelofibrosis ( MF). The aim of this work was to determine the prevalence and profile of ASXL1 mutations in MF. Methods We analyzed mutations in ASXL1 in 70 consecutive MF patients from 8 Spanish hospitals by means of Sanger sequencing, as well as JAK2, CALR , and MPL mutations. Results ASXL1 mutations were found in 16/70 (23%) of cases, most commonly p.Gly646TrpfsX12 (5/16). Most mutations (13/16) were frameshift mutations. Of 54 ASXL1- wild-type patients, 32 (59%) had at least one single nucleotide polymorphism ( SNP), 27 of them had g.78128 C> T, g.79017 A> C, and g.79085 T> C [triple SNP ( TSNP) patients]. The 5-yr overall survival probability of TSNP patients was 67% (95% CI, 43-91%) vs. 90% (95% CI, 77-100%) in ASXL1- WT patients ( P = 0.152). Conclusion ASXL1 mutations were found in 23% of cases, p.Gly646TrpfsX12 being the most frequent. About 85% of mutations were found only in individual cases and 46% had not previously been reported, a pattern also seen in other series. Fifty percent of ASXL1- WT patients had a combination of three specific SNPs that might have a prognostic correlation that needs to be determined in larger series. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

49. Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy.

Author

Kelleher, Nicholas, Gallardo, David, González-Campos, José, Hernández-Rivas, Jesús M., Montesinos, Pau, Sarrá, Josep, Gil, Cristina, Barba, Pere, Guàrdia, Ramon, Brunet, Salut, Bernal, Teresa, Martínez, Maria-Pilar, Abella, Eugènia, Bermúdez, Arantxa, Sánchez-Delgado, Magdalena, Antònia, Cladera, Gayoso, Jorge, Calbacho, María, and Ribera, Josep-Maria

Subjects
*LYMPHOBLASTIC leukemia, *HUMAN cytogenetics, *PROGNOSIS, *CANCER chemotherapy, *RADIOTHERAPY, *PATIENTS
Abstract

Acute lymphoblastic leukemia (ALL) following solid organ or hematologic malignancy (secondary ALL, s-ALL) is not well characterized. We analyzed the characteristics and outcome of patients with s-ALL and compared them with those of patients with de novo- ALL. Of 448 patients, 24 (5%) had previous neoplasia. Sixteen patients had received previous cytotoxic therapy (therapy-associated ALL, t-ALL), and eight had not (antecedent-malignancy ALL, am-ALL). Except for more advanced age in patients with s-ALL, no statistically significant differences were observed in WBC count, CNS involvement, immunophenotype or cytogenetics between the groups, nor in complete remission (t-ALL: 94%; am-ALL: 75%; de novo-ALL: 85%), 3-year remission duration (58%; 50%; 72%), overall survival (71%; 38%; 60%) or event-free survival (53%, 38%; 53%). Our study did not show poor clinical or cytogenetic features or inferior outcome in ALL patients with antecedent neoplastic disease, irrespective of the type of treatment received for the neoplasia. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

50. Prognostic Impact of MLL Partial Tandem Duplication in Acute Myeloid Leukemia of Intermediate Cytogenetic Risk: A Subgroup Analysis of Cetlam Protocol 2003 & 2012

Author

Pratcorona, Marta, Garrido, Ana, Brunet, Salut, Esteve, Jordi, Estivill, María Camino, Queipo De Llano, M. Paz, Vives, Susana, Arnan, Montserrat, Gallardo, David, Tormo, Mar, Garcia-Guiñon, Antoni, Sampol, Antonia, Salamero, Olga, Martí, Josep Ma, Bargay, Joan, Pedro, M Carmen, Hoyos, Montserrat, Diaz-Beya, Marina, Escoda, Lourdes, Guàrdia, Ramon, Ribera, Josep, Sierra, Jorge, and Nomdedeu, Josep F.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results